Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs lansoprazole for healing and maintenance of erosive esophagitis
2019-002579-33Phase 3Unknown
- Sponsor
- Phathom Pharmaceuticals
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan in erosive esophagitis (EE) (5 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Healing Phase primary endpoint and Maintenance Phase primary endpoint. Status: unknown.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on 2019-002579-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002579-33.